- Home
- JBDI vs NRSN Comparison
JBDI vs NRSN Comparison
Compare JBDI & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JBDI | NRSN |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7M | 29.8M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JBDI | NRSN |
|---|---|---|
| Price | $0.93 | $1.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 23.7K | ★ 389.7K |
| Earning Date | 01-01-0001 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,445,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.49 | $0.81 |
| 52 Week High | $3.00 | $2.60 |
Technical Indicators
Market Signals| Indicator | JBDI | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 39.20 | 55.35 |
| Support Level | $0.87 | $1.07 |
| Resistance Level | $0.94 | $1.24 |
| Average True Range (ATR) | 0.09 | 0.14 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 61.36 | 75.68 |
Price Performance
Historical ComparisonAbout JBDI JBDI Holdings Limited Ordinary Shares
JBDI Holdings Ltd is a supplier of Reconditioned and new Containers in Singapore. Its products include Reconditioned and new steel drums, plastic drums, carboys and IBCs.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.